Page 25 - DIY Investor Magazine - Issue 28
P. 25

     ‘THE COVID-19 CRISIS SHONE A LIGHT ON THE INCREDIBLE INNOVATION WITHIN THE HEALTHCARE INDUSTRY’ More information on Polar Capital Global Healthcare Trust PLC here > To buy this trust login to your EQi account Select Polar Capital Global Healthcare Trust - GB00B6832P16 Important Information This document constitutes a financial promotion pursuant to section 21 of the Financial Services and Markets Act 2000 and has been prepared and issued by Polar Capital LLP (“Polar Capital”). Polar Capital is a limited liability partnership with registered number OC314700, which is authorised and regulated by the UK Financial Conduct Authority (“FCA”) and is registered as an investment advisor with the US Securities & Exchange Commission (“SEC”). A list of members is open to inspection at the registered office, 16 Palace Street, London, SW1E 5JD. This document does not constitute, or form part of, any offer or invitation to sell or purchase, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or any part of it, or the fact of its distribution, form the basis of or be relied on in connection with or act as any inducement to enter into, any contract therefore. It is for information purposes only and is not designed to contain information material to an investor’s decision to invest in the Company. Polar Capital is not rendering legal or accounting advice through this announcement; viewers should contact their legal and accounting professionals for such information. All opinions and estimates in this announcement constitute the best judgement of Polar Capital as of the date hereof, but are subject to change without notice, and do not necessarily represent the views of Polar Capital. Potential investors should be aware that any investment in the Company is speculative, involves a high degree of risk, and could result in the loss of all or substantially all their investment. Results can be positively or negatively affected by market conditions beyond the control of the Company or any other person. This announcement may include statements that are, or may be deemed to be, “forward-looking statements”. These forward- looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. This document has not been approved by any competent regulatory or supervisory authority.     Clinical Research Organisations (CROs) are well positioned to capitalise on this opportunity, offering services that include consulting, clinical trial recruitment and execution, and commercial expertise. Indeed, CROs Iqvia, PPD, PRA Health Sciences and Syneos all produced strong Q4 2020 financial results, coupled with robust outlooks for 2021. It is also reasonable to argue that the management of ICON share our views given their decision to part with $12bn to purchase PRA Health Sciences. The COVID-19 crisis shone a light on the incredible innovation within the healthcare industry, as well as highlighting the importance and value of preventative medicine. Prevention is, or should be, the cornerstone of all public healthcare systems given the obvious benefits of early intervention and better outcomes for patients. What better example is there than the COVID-19 vaccines? Not only are they highly effective at preventing COVID-19, but they are also showing their real-world value in terms of preventing hospitalisations, an invaluable property given the acute pressure being exerted on healthcare systems globally. Looking further out, logic would dictate that the recent capital investments made in terms of diagnostics infrastructure will be utilised rather than left to gather dust. Testing menus will expand, early diagnoses will become more wide-spread and biomarkers will be used to identify conditions early. If true, then we can look forward to greater co-ordination of care, targeted treatment regimens and superior outcomes. 25 DIY Investor Magazine | Apr 2021 

   23   24   25   26   27